GLP-1 agents have reshaped the management of obesity, and the market continues to accelerate as new agents and indications emerge. On December 22, 2025, the FDA approved the first...
By Andy Gillespie, PharmD, AVP, Clinical Strategy, SlateRx As 2025 comes to a close, it’s time to look back at the year and how new therapies, evolving regulatory pressures,...
Managing pharmacy benefits is no longer a simple “set it and forget it” task. With ultra-high-cost therapies in market, and new benefit solutions emerging rapidly, employers face mounting pressure...
